Anjarium Biosciences announced the conclusion of a series A funding round amounting to 55.5 million Swiss francs on Thursday. It was led by the life sciences investor Abingworth and the European investment company Gimv. Omega Funds, Pfizer Ventures and Surveyor Capital were also “significantly” involved according to a press release. Bali Muralidhar of Abingworth, Bram Vanparys of Gimv, and Dina Chaya of Omega Funds will join the company’s board of directors.
Anjarium develops innovative nonviral gene therapies. To do so, the biotech company combines the latest scientific findings and expertise at the intersection between genetic medicine, synthetic biology, and nanoparticle technology with its innovative hybridosome technology. It develops and produces efficient, tissue-targeting gene therapies, which aim to provide therapeutic strategies that are more long-term, precise and personalized for a range of serious genetic diseases.
Moreover, this new class of gene therapeutics offers the possibility of remedying the key failings of current viral gene therapies. Founder and CSO of Anjarium Biosciences Joël de Beer states: “As the limitations of conventional viral-vector based gene therapies to deliver optimal patient outcomes become increasingly evident, a fully non-viral approach represents an exciting new therapeutic opportunity.”
According to information provided by Anjarium, it plans to use the proceeds from this funding round to expand its team, further develop its “ground-breaking” platform, and drive forward clinical development of several therapeutic programs.
Anjarium Biosciences is headquartered at the Bio-Technopark Schlieren-Zürich.